Drug intelligence / Profile preview

GXV-002

Development stage: Preclinical
Lead developer: GEXVal
Modality: Small Molecules
Administration: Oral

Overview

GXV-002 is an investigational small molecule calcium-sensing receptor (CaSR) antagonist (calcilytic) being developed by GEXVal for the treatment of pulmonary arterial hypertension (PAH) and rare genetic cardiovascular diseases. Originally developed by Takeda, the asset was in-licensed by GEXVal, which is currently advancing it through IND-enabling studies. GXV-002 has received Orphan Drug Designation (ODD) from the US FDA for the treatment of PAH. By targeting CaSR, GXV-002 aims to address the underlying vascular remodeling and vasoconstriction associated with PAH and other rare cardiovascular conditions.

Targets

CaSR (Extracellular calcium-sensing receptor)

Beyond the preview

Go deeper on GXV-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GXV-002.

Explore the full profile